Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Protein shake after liver transplant: simple fix for muscle loss?

NCT ID NCT07168369

Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether giving liver transplant patients a daily high-protein drink for 12 weeks helps them maintain muscle mass. Thirty patients on the transplant list took part. Researchers measured muscle mass with CT scans and tracked how well patients stuck with the drink. The main goal was to see if such a study is even possible, not yet to prove the drink works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
protein and energy-rich oral supplement (Ensure Protéine Max or Boost Diabetic)
What this could lead to
If successful, this could show that a simple nutritional drink helps liver transplant patients keep muscle strength and improve recovery.
What could go wrong
This is a very small feasibility study (30 people) with no phase, so results are preliminary. The supplement may not prevent muscle loss or improve outcomes in larger, longer trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Feb 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with cirrhosis listed for LT * French or English speaking Exclusion Criteria: * patients awaiting multiple organ transplants * patients with acute liver failure or hepatocellular carcinoma * patients who stayed in the intensive care unit for more than 30 days after LT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver transplant

Contacts and locations

Locations

  • Centre de recherche du Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 0A9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.